-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Electra Therapeutics announced the completion of an $84 million Series B financing to develop innovative therapeutics targeting signaling regulatory proteins (SIRPs)
Electra is building a pipeline of new therapeutics targeting SIRP
▲Electra product pipeline (Image source: Electra's official website)
ELA026 is a monoclonal antibody specifically designed to treat severe inflammatory diseases with abnormal myeloid and T cell activity
▲ Pathological mechanism of sHLH (Image source: Electra official website)
References:
[1] Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer.
(Original abridged)